Women were treated with GnRH agonist (Superfact, Sanofi-Aventis, Frankfurt, Germany) using the long protocol or GnRH antagonist protocol and recombinant FSH (Gonal F, Merk Serono, Darmstadt, Germany). When two or more follicles reached 18 mm in diameter, a dose of 10,000 IU of hCG (Ovidrel, Merk Serono) was administered. Oocyte retrieval was performed 36 hours after hCG injection.
Superfact
Manufactured by Sanofi
Sourced in Germany, France, Canada
Superfact is a high-performance laboratory instrument designed for precise and reliable analysis. The core function of Superfact is to perform advanced spectroscopic measurements, enabling researchers to obtain accurate data and insights from their samples.
Automatically generated - may contain errors
4 protocols using superfact
1
Controlled Ovarian Stimulation Protocol
2
Gonadotropin Protocols for IVF Stimulation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Gonadotropin-releasing hormone (GnRH) antagonist and agonist protocols were used in this study. Gonadotropin doses were formulated according to the patient's antral follicular count, antimüllerian hormone, and previous response to stimulation. Transvaginal ultrasound was performed to monitor follicular response to stimulation and gonadotropin doses were adjusted accordingly. Final oocyte maturation was triggered with hCG (Ovidrel; Merck, Kenilworth, NJ, USA) with or without GnRH agonist (Superfact; Sanofi-Aventis, Paris, France) when the mean diameter of ≥ 2 follicles sized ≥ 17 mm. Ultrasound-guided oocyte-retrieval under conscious sedation was performed 34–36 hours after the trigger.
Luteal phase support was provided either with progesterone vaginal suppositories, such as Utrogestan (Besins Healthcare, Paris, France), Lutinus (Ferring, Saint-Prex, Switzerland), Crinone gel 8% (Merck) or intramuscular injections (Sugest; Sanzyme Ltd., Banjara Hills, India) starting on the day of fresh ET. For frozen-thawed ET, luteal phase support was given starting from 5 days before the ET.
Luteal phase support was provided either with progesterone vaginal suppositories, such as Utrogestan (Besins Healthcare, Paris, France), Lutinus (Ferring, Saint-Prex, Switzerland), Crinone gel 8% (Merck) or intramuscular injections (Sugest; Sanzyme Ltd., Banjara Hills, India) starting on the day of fresh ET. For frozen-thawed ET, luteal phase support was given starting from 5 days before the ET.
3
Agonist and Antagonist Protocols for IVF
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Women were treated with a gonadotropin-releasing hormone agonist (Superfact; Sanofi-Aventis, Frankfurt, Germany) using the long protocol or a gonadotropin-releasing hormone antagonist protocol and recombinant follicle-stimulating hormone (Gonal F; Merck Serono, Darmstadt, Germany). When two or more follicles reached 18 mm in diameter, 10,000 IU of human chorionic gonadotropin (hCG) (IVF-C; LG Chemical, Seoul, Korea) or Ovidrel (Merck Serono) was administered.
4
Ovarian Stimulation Protocols for Poor Responders
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Ovarian stimulation was performed by means of one of the following protocols: microdose-flare protocol, fixed gonadotrophinreleasing hormone (GnRH) antagonist protocol and mid-luteal long GnRH agonist protocol. Briefly, ovarian stimulation was performed with gonadotrophins (Gonal-F, EMD-Serono Inc., Canada; Puregon, Merck Inc., Canada; Menopur, Ferring Pharmaceuticals Inc., Canada), ovulation was suppressed with GnRH antagonist (Cetrotide, EMD-Serono Inc.; Orgalutran, Merck Inc.) or GnRH agonist (Superfact, Sanofi-Aventis Inc., Canada). No standard stimulation protocol is used for patients with POR in our clinic; protocol and gonadotrophin dose were based on AFC, Day 3 FSH and the results of previous IVF cycles. Gonadotrophin dose was ≥300 IU FSH per day. After 5-7 days of stimulation, FSH dose was adjusted based on ultrasound scan and serum oestradiol level. The maximal dose of FSH was 600 IU. When ideally two follicles attained a mean diameter of 17 mm, 250 µg of human recombinant chorionic gonadotrophin was administered (Ovidrel, EMD-Serono Inc.). Oocyte retrieval by an ultrasound guided transvaginal approach was scheduled 36-38 h later.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!